Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Pfizer looking to RSV vaccine for fresh growth

Data in maternal setting set pharma up to seek approval this year

November 2, 2022 1:03 AM UTC

A second Phase III RSV readout from Pfizer puts the pharma on track for a potential vaccine approval where competitors have fallen short.

Along with its 3Q22 earnings Tuesday, Pfizer Inc. (NYSE:PFE) said RSVpreF delivered efficacy of 81.8% against severe medically attended lower respiratory track illness (MA-LRTI) in infants from birth through the first 90 days of life in the Phase III MATISSE trial in which the respiratory syncytial virus (RSV) vaccine is given to pregnant women to protect newborns. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Pfizer Inc.